用口服里瓦斯蒂格明治疗抗胆固醇妄症:一个案例报告
Christopher Karousatos1, Lauren Murphy1
1Department of Emergency Medicine, Lewis Katz School of Medicine at Temple University, Philadelphia, Philadelphia.
抗胆毒性是一种常见的急诊室呈现. 口服里瓦斯蒂格明为逆转抗胆固醇狂妄症提供了可行的替代品,特别是在药物短缺期间.
科学领域:
- 紧急医疗 紧急医疗
- 临床毒理学 临床毒理学
- 药理学 药理学是指药理学的学科.
背景情况:
- 抗胆固醇毒性经常在急诊室看到.
- 菲索斯蒂格,一种关键的解毒剂,在美国面临着严重的国家药物短缺.
- 利瓦斯蒂格因正在作为一种潜在的替代治疗方法进行研究.
研究的目的:
- 报告使用口服里瓦斯蒂格明药成功逆转抗胆固醇狂妄症的病例.
- 突出利瓦斯蒂格明作为一种潜在的替代物质斯蒂格明.
主要方法:
- 一名33岁的男性在怀疑过量后出现了抗胆固醇毒性症状.
- 患者接受口服里瓦斯蒂格明 (起初为4.5毫克) 治疗妄症.
- 监测临床反应和症状的复发.
主要成果:
- 患者的抗胆性狂妄症在用口服里瓦斯蒂格治疗后得到缓解.
- 一次重复剂量是必要的,但妄想并没有复发.
- 治疗提供了长时间的兴奋控制.
结论:
- 口服里瓦斯蒂格明可以有效地用于逆转抗胆固醇狂妄症.
- 紧急医生可以考虑使用rivastigmine (4.5-6毫克的初始剂量),当不存在physostigmine时,与专家协商.
更多相关视频
05:54MRI-guided Focused Ultrasound Thalamotomy for Patients with Medically-refractory Essential Tremor
Published on: December 13, 2017
07:09Subcutaneous Administration of Muscarinic Antagonists and Triple-Immunostaining of the Levator Auris Longus Muscle in Mice
Published on: September 8, 2011
相关概念视频
Alzheimer's Disease: Treatment
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Anticholinesterase Agents: Poisoning and Treatment
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
Indirect-Acting Cholinergic Agonists: Pharmacological Actions
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
Cholinergic Antagonists: Therapeutic Uses
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
Direct-Acting Cholinergic Agonists: Therapeutic Uses
